BACKGROUND: Sox10 is a transcription factor associated with neural crest development. Its expression has been reported in melanocytes and peripheral nerve sheath cells and their associated tumors. OBJECTIVE: To assess Sox10 sensitivity in benign and malignant melanocytic neoplasms of various histologic subtypes and to discern the specificity of Sox10 in distinguishing between melanocytic neoplasms and fibrohistiocytic and histiocytic mimickers. METHODS: Sox10 expression was examined by immunohistochemistry in 145 cases of formalin-fixed paraffin-embedded tissue, including benign and malignant melanocytic lesions of various histologies and stages (n = 83), fibrohistiocytic and histiocytic lesions (n = 33), and peripheral nerve sheath tumors (n = 19), among others (n = 10). RESULTS: Immunoreactivity with Sox10 was observed in 100% (83/83) of benign and malignant melanocytic lesions of various subtypes, as well as in 100% (19/19) of benign and malignant peripheral nerve sheath lesions. Among the fibrohistiocytic proliferations and histiocytoses examined, Sox10 was negative in all cases (0/33). Sox10 expression did not vary by histologic subtype in nevi or melanoma; however, both the percentage of tumor nuclei demonstrating Sox10 expression and the intensity of expression were inversely correlated with malignant potential (nevi, melanoma in situ, invasive and metastatic melanoma) (P < .001, P = .016, respectively). Malignant peripheral nerve sheath tumors also showed decreased mean Sox10 expression and decreased intensity of expression when compared with benign counterparts (P < .001, P = .021, respectively). LIMITATIONS: This is a retrospective study with 145 cases included. CONCLUSIONS: Sox10 is a highly sensitive marker for melanocytic proliferations and may be useful diagnostically when the differential diagnosis includes fibrohistiocytic and histiocytic proliferations demonstrating S100 expression.
BACKGROUND:Sox10 is a transcription factor associated with neural crest development. Its expression has been reported in melanocytes and peripheral nerve sheath cells and their associated tumors. OBJECTIVE: To assess Sox10 sensitivity in benign and malignant melanocytic neoplasms of various histologic subtypes and to discern the specificity of Sox10 in distinguishing between melanocytic neoplasms and fibrohistiocytic and histiocytic mimickers. METHODS:Sox10 expression was examined by immunohistochemistry in 145 cases of formalin-fixed paraffin-embedded tissue, including benign and malignant melanocytic lesions of various histologies and stages (n = 83), fibrohistiocytic and histiocytic lesions (n = 33), and peripheral nerve sheath tumors (n = 19), among others (n = 10). RESULTS: Immunoreactivity with Sox10 was observed in 100% (83/83) of benign and malignant melanocytic lesions of various subtypes, as well as in 100% (19/19) of benign and malignant peripheral nerve sheath lesions. Among the fibrohistiocytic proliferations and histiocytoses examined, Sox10 was negative in all cases (0/33). Sox10 expression did not vary by histologic subtype in nevi or melanoma; however, both the percentage of tumor nuclei demonstrating Sox10 expression and the intensity of expression were inversely correlated with malignant potential (nevi, melanoma in situ, invasive and metastatic melanoma) (P < .001, P = .016, respectively). Malignant peripheral nerve sheath tumors also showed decreased mean Sox10 expression and decreased intensity of expression when compared with benign counterparts (P < .001, P = .021, respectively). LIMITATIONS: This is a retrospective study with 145 cases included. CONCLUSIONS:Sox10 is a highly sensitive marker for melanocytic proliferations and may be useful diagnostically when the differential diagnosis includes fibrohistiocytic and histiocytic proliferations demonstrating S100 expression.
Authors: Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Wojciech Biernat; Piotr Czapiewski; Janusz Kopczynski; Lester D Thompson; Jerzy Lasota; Zengfeng Wang; John F Fetsch Journal: Am J Surg Pathol Date: 2015-06 Impact factor: 6.394
Authors: Rachel E Beard; Daniel Abate-Daga; Shannon F Rosati; Zhili Zheng; John R Wunderlich; Steven A Rosenberg; Richard A Morgan Journal: Clin Cancer Res Date: 2013-09-10 Impact factor: 12.531
Authors: Hong Gang Liu; Max Xiangtian Kong; Qian Yao; Shu Yi Wang; Robert Shibata; Herman Yee; Frank Martiniuk; Beverly Y Wang Journal: Head Neck Pathol Date: 2012-06-27
Authors: Yian Ann Chen; Jamie K Teer; Zeynep Eroglu; Jheng-Yu Wu; John M Koomen; Florian A Karreth; Jane L Messina; Keiran S M Smalley Journal: Semin Cancer Biol Date: 2019-11-02 Impact factor: 15.707
Authors: B K Kleinschmidt-DeMasters; Andrew M Donson; Abby M Richmond; Melike Pekmezci; Tarik Tihan; Nicholas K Foreman Journal: J Neuropathol Exp Neurol Date: 2016-03-04 Impact factor: 3.685
Authors: Ashley Cimino-Mathews; Andrea P Subhawong; Hillary Elwood; Hind Nassar Warzecha; Rajni Sharma; Ben Ho Park; Janis M Taube; Peter B Illei; Pedram Argani Journal: Hum Pathol Date: 2012-12-20 Impact factor: 3.466
Authors: Richard J Straker; Laura A Taylor; Madalyn G Neuwirth; Andrew J Sinnamon; Adrienne B Shannon; James Abbott; John T Miura; Emily Y Chu; Xiaowei Xu; Giorgos C Karakousis Journal: Am J Dermatopathol Date: 2022-01-01 Impact factor: 1.319